{
  "drugName": "Mounjaro",
  "setId": "d2d7da5d-ad07-4228-955f-cf7e355c8cc0",
  "slug": "mounjaro-d2d7da5",
  "labeler": "Eli Lilly and Company",
  "label": {
    "boxedWarning": "<div class=\"Warning\" id=\"boxed-warning\"><div><h2 class=\"Warning\"><span class=\"Bold\">WARNING: RISK OF THYROID C-CELL TUMORS</span></h2><h2 class=\"Warning\"><span class=\"Bold Italics\">See full prescribing information for complete boxed warning.</span></h2><ul class=\"Disc\"><li><span class=\"Bold\">Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined (<a href=\"#s10\">5.1</a>, <a href=\"#s72\">13.1</a>).</span></li><li><span class=\"Bold\">MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (<a href=\"#s8\">4</a>, <a href=\"#s10\">5.1</a>).</span></li></ul></div></div>",
    "genericName": "tirzepatide",
    "labelerName": "Eli Lilly and Company",
    "productType": "HUMAN PRESCRIPTION DRUG LABEL",
    "effectiveTime": "20250114",
    "title": "MOUNJARO",
    "indicationsAndUsage": "<section class=\"Section\" data-sectioncode=\"34067-9\"><a name=\"s2\"></a><a name=\"section-1\"></a><p></p><h1>1 INDICATIONS AND USAGE</h1><p class=\"First\">MOUNJARO<span class=\"Sup\">®</span> is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s3\"></a><a name=\"section-1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Limitations of Use</span></p><ul class=\"Disc\"><li>MOUNJARO has not been studied in patients with a history of pancreatitis <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s11\">5.2</a>)]</span>.</li><li>MOUNJARO is not indicated for use in patients with type 1 diabetes mellitus.</li></ul></div></section>",
    "dosageAndAdministration": "<section class=\"Section\" data-sectioncode=\"34068-7\"><a name=\"s4\"></a><a name=\"section-2\"></a><p></p><h1>2 DOSAGE AND ADMINISTRATION</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s5\"></a><a name=\"section-2.1\"></a><p></p><h2>2.1 Dosage</h2><ul class=\"Disc\"><li>The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s15\">5.6</a>) and Adverse Reactions (<a href=\"#s19\">6.1</a>)]</span>. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.</li><li>After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.</li><li>If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.</li><li>The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.</li><li>If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.</li><li>The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).</li></ul></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s6\"></a><a name=\"section-2.2\"></a><p></p><h2>2.2 Important Administration Instructions</h2><ul class=\"Disc\"><li>Prior to initiation, train patients and caregivers on proper injection technique <span class=\"Italics\">[see <a href=\"#s97\">Instructions for Use</a>]</span>.</li><li>Instruct patients using the single-dose vial to use a syringe appropriate for dose administration (e.g., a 1 mL syringe capable of measuring a 0.5 mL dose).</li><li>Administer MOUNJARO once weekly, any time of day, with or without meals.</li><li>Inject MOUNJARO subcutaneously in the abdomen, thigh, or upper arm.</li><li>Rotate injection sites with each dose.</li><li>Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen.</li><li>When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.</li></ul></div></section>",
    "dosageFormsAndStrengths": "<section class=\"Section\" data-sectioncode=\"43678-2\"><a name=\"s7\"></a><a name=\"section-3\"></a><p></p><h1>3 DOSAGE FORMS AND STRENGTHS</h1><p class=\"First\">Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens or single-dose vials, each available in the following strengths:</p><ul class=\"Disc\"><li>2.5 mg/0.5 mL</li><li>5 mg/0.5 mL</li><li>7.5 mg/0.5 mL</li><li>10 mg/0.5 mL</li><li>12.5 mg/0.5 mL</li><li>15 mg/0.5 mL</li></ul></section>",
    "warningsAndPrecautions": "<section class=\"Section\" data-sectioncode=\"43685-7\"><a name=\"s9\"></a><a name=\"section-5\"></a><p></p><h1>5 WARNINGS AND PRECAUTIONS</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s10\"></a><a name=\"section-5.1\"></a><p></p><h2>5.1 Risk of Thyroid C-Cell Tumors</h2><p class=\"First\">In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures <span class=\"Italics\">[see Nonclinical Toxicology (<a href=\"#s72\">13.1</a>)]</span>. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.</p><p>MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).</p><p>Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values &gt;50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s11\"></a><a name=\"section-5.2\"></a><p></p><h2>5.2 Pancreatitis</h2><p class=\"First\">Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.</p><p>In clinical studies, 14 events of acute pancreatitis were confirmed by adjudication in 13 MOUNJARO-treated patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). MOUNJARO has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on MOUNJARO.</p><p>After initiation of MOUNJARO, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue MOUNJARO and initiate appropriate management.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s12\"></a><a name=\"section-5.3\"></a><p></p><h2>5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin</h2><p class=\"First\">Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia <span class=\"Italics\">[see Adverse Reactions (<a href=\"#s19\">6.1</a>), Drug Interactions (<a href=\"#s33\">7.1</a>)]</span>.</p><p>The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s13\"></a><a name=\"section-5.4\"></a><p></p><h2>5.4 Hypersensitivity Reactions</h2><p class=\"First\" style=\"border-left:1px solid;\"><span class=\"XmChange\"></span>Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with MOUNJARO. If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in MOUNJARO <span class=\"Italics\">[see Contraindications (<a href=\"#s8\">4</a>), Adverse Reactions (<a href=\"#s31\">6.2</a>)]</span>.</p><p>Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with MOUNJARO.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s14\"></a><a name=\"section-5.5\"></a><p></p><h2>5.5 Acute Kidney Injury</h2><p class=\"First\">MOUNJARO has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea <span class=\"Italics\">[see Adverse Reactions (<a href=\"#s19\">6.1</a>)]</span>. These events may lead to dehydration, which if severe could cause acute kidney injury.</p><p>In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe gastrointestinal adverse reactions.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s15\"></a><a name=\"section-5.6\"></a><p></p><h2>5.6 Severe Gastrointestinal Adverse Reactions</h2><p class=\"First\" style=\"border-left:1px solid;\"><span class=\"XmChange\"></span>Use of MOUNJARO has been associated with gastrointestinal adverse reactions, sometimes severe <span class=\"Italics\">[see Adverse Reactions <a href=\"#s19\">6.1</a>]</span>. In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%). </p><p>MOUNJARO has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s16\"></a><a name=\"section-5.7\"></a><p></p><h2>5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy</h2><p class=\"First\">Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. MOUNJARO has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s17\"></a><a name=\"section-5.8\"></a><p></p><h2>5.8 Acute Gallbladder Disease</h2><p class=\"First\">Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.</p><p>In MOUNJARO placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s17a\"></a><a name=\"section-5.9\"></a><p></p><h2>5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation</h2><p class=\"First\" style=\"border-left:1px solid;\"><span class=\"XmChange\"></span>MOUNJARO delays gastric emptying <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s54\">12.2</a>)]</span>. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.</p><p style=\"border-left:1px solid;\"><span class=\"XmChange\"></span>Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking MOUNJARO, including whether modifying preoperative fasting recommendations or temporarily discontinuing MOUNJARO could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking MOUNJARO.</p></div></section>",
    "adverseReactions": "<section class=\"Section\" data-sectioncode=\"34084-4\"><a name=\"s18\"></a><a name=\"section-6\"></a><p></p><h1>6 ADVERSE REACTIONS</h1><p class=\"First\">The following serious adverse reactions are described below or elsewhere in the prescribing information:</p><ul class=\"Disc\"><li>Risk of Thyroid C-cell Tumors <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s10\">5.1</a>)]</span></li><li>Pancreatitis <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s11\">5.2</a>)]</span></li><li>Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s12\">5.3</a>)]</span></li><li>Hypersensitivity Reactions <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s13\">5.4</a>)]</span></li><li>Acute Kidney Injury <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s14\">5.5</a>)]</span></li><li>Severe Gastrointestinal Adverse Reactions <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s15\">5.6</a>)]</span></li><li>Diabetic Retinopathy Complications <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s16\">5.7</a>)]</span></li><li>Acute Gallbladder Disease <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s17\">5.8</a>)]</span></li><li>Pulmonary Aspiration During General Anesthesia or Deep Sedation <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s17a\">5.9</a>)]</span></li></ul><div class=\"Section\" data-sectioncode=\"90374-0\"><a name=\"s19\"></a><a name=\"section-6.1\"></a><p></p><h2>6.1 Clinical Trials Experience</h2><p class=\"First\">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s20\"></a><a name=\"section-6.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Pool of Two Placebo-Controlled Clinical Trials</span></p><p>The data in <a href=\"#t1\">Table 1</a> are derived from 2 placebo-controlled trials [1 monotherapy trial (SURPASS-1) and 1 trial in combination with basal insulin with or without metformin (SURPASS-5)] in adult patients with type 2 diabetes mellitus <span class=\"Italics\">[see Clinical Studies (<a href=\"#s75\">14.2</a>, <a href=\"#s80\">14.4</a>)]</span>. These data reflect exposure of 718 patients to MOUNJARO and a mean duration of exposure to MOUNJARO of 36.6 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 54% were male. The population was 57% White, 27% Asian, 13% American Indian or Alaska Native, and 3% Black or African American; 25% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.1%. As assessed by baseline fundoscopic examination, 13% of the population had retinopathy. At baseline, eGFR was ≥90 mL/min/1.73 m<span class=\"Sup\">2</span> in 53%, 60 to 90 mL/min/1.73 m<span class=\"Sup\">2</span> in 39%, 45 to 60 mL/min/1.73 m<span class=\"Sup\">2</span> in 7%, and 30 to 45 mL/min/1.73 m<span class=\"Sup\">2</span> in 1% of patients.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s21\"></a><a name=\"section-6.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Pool of Seven Controlled Clinical Trials</span></p><p>Adverse reactions were also evaluated in a larger pool of adult patients with type 2 diabetes mellitus participating in seven controlled clinical trials which included two placebo-controlled trials (SURPASS-1 and -5), three trials of MOUNJARO in combination with metformin, sulfonylureas, and/or SGLT2 Inhibitors (SURPASS-2, -3, -4) <span class=\"Italics\">[see Clinical Studies (<a href=\"#s76\">14.3</a>)]</span> and two additional trials conducted in Japan. In this pool, a total of 5119 adult patients with type 2 diabetes mellitus were treated with MOUNJARO for a mean duration of 48.1 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 58% were male. The population was 65% White, 24% Asian, 7% American Indian or Alaska Native, and 3% Black or African American; 38% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.3%. As assessed by baseline fundoscopic examination, 15% of the population had retinopathy. At baseline, eGFR was ≥90 mL/min/1.73 m<span class=\"Sup\">2</span> in 52%, 60 to 90 mL/min/1.73 m<span class=\"Sup\">2</span> in 40%, 45 to 60 mL/min/1.73 m<span class=\"Sup\">2</span> in 6%, and 30 to 45 mL/min/1.73 m<span class=\"Sup\">2</span> in 1% of patients.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s22\"></a><a name=\"section-6.1.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">Common Adverse Reactions</span></p><p><a href=\"#t1\">Table 1</a> shows common adverse reactions, not including hypoglycemia, associated with the use of MOUNJARO in the pool of placebo-controlled trials. These adverse reactions occurred more commonly on MOUNJARO than on placebo and occurred in at least 5% of patients treated with MOUNJARO.</p><a name=\"t1\"></a><table width=\"100%\"><caption><span>Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in ≥5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus</span></caption><col align=\"left\" width=\"24.040%\"/><col align=\"left\" width=\"19.240%\"/><col align=\"left\" width=\"18.260%\"/><col align=\"left\" width=\"20.200%\"/><col align=\"left\" width=\"18.260%\"/><tfoot><tr class=\"First Last\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\">Note: Percentages reflect the number of patients who reported at least 1 occurrence of the adverse reaction.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Adverse Reaction</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Placebo<br/>(N=235)<br/>%</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO <br/>5 mg<br/>(N=237)<br/>%</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO <br/>10 mg<br/>(N=240)<br/>%</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO <br/>15 mg<br/>(N=241)<br/>%</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"middle\">Nausea</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">15</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">18</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Diarrhea</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">12</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">17</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Decreased Appetite</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">10</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">11</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"middle\">Vomiting</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"middle\">Constipation</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"middle\">Dyspepsia</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">5</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"middle\">Abdominal Pain</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">5</td></tr></tbody></table><p>In the pool of seven clinical trials, the types and frequency of common adverse reactions, not including hypoglycemia, were similar to those listed in <a href=\"#t1\">Table 1</a>.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s23\"></a><a name=\"section-6.1.4\"></a><p></p><p class=\"First\"><span class=\"Italics\">Gastrointestinal Adverse Reactions</span></p><p>In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%). More patients receiving MOUNJARO 5 mg (3.0%), MOUNJARO 10 mg (5.4%), and MOUNJARO 15 mg (6.6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.</p><p>The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s24\"></a><a name=\"section-6.1.5\"></a><p></p><p class=\"First\"><span class=\"Underline\">Other Adverse Reactions</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s25\"></a><a name=\"section-6.1.5.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Hypoglycemia</span></p><p><a href=\"#t2\">Table 2</a> summarizes the incidence of hypoglycemic events in the placebo-controlled trials.</p><a name=\"t2\"></a><table width=\"100%\"><caption><span>Table 2: Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Adult Patients with Type 2 Diabetes Mellitus</span></caption><col align=\"left\" width=\"32.320%\"/><col align=\"left\" width=\"16.660%\"/><col align=\"left\" width=\"16.680%\"/><col align=\"left\" width=\"16.680%\"/><col align=\"left\" width=\"17.660%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\">* Reflects the study treatment period. Data include events occurring during 4 weeks of treatment-free safety follow up. Events after introduction of a new glucose-lowering treatment are excluded.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\">** Episodes requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"5\" valign=\"top\"></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Placebo<br/></span><br/><span class=\"Bold\">%</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO <br/>5 mg</span><br/><span class=\"Bold\">%</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO <br/>10 mg</span><br/><span class=\"Bold\">%</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO <br/>15 mg</span><br/><span class=\"Bold\">%</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Monotherapy</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">      (40 weeks)*</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">N=115</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">N=121</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">N=119</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">N=120</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Blood glucose &lt;54 mg/dL</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Severe hypoglycemia**</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Add-on to Basal Insulin with or without Metformin</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">      (40 weeks)*</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">N=120</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">N=116</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">N=119</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">N=120</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Blood glucose &lt;54 mg/dL</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">13</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">16</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">19</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">14</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Severe hypoglycemia**</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1</td></tr></tbody></table><p>Hypoglycemia was more frequent when MOUNJARO was used in combination with a sulfonylurea <span class=\"Italics\">[see Clinical Studies (<a href=\"#s73\">14</a>)]</span>. In a clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level &lt;54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s26\"></a><a name=\"section-6.1.5.2\"></a><p></p><p class=\"First\"><span class=\"Italics\">Heart Rate Increase</span></p><p>In the pool of placebo-controlled trials, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of ≥15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. The clinical relevance of heart rate increases is uncertain.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s27\"></a><a name=\"section-6.1.5.3\"></a><p></p><p class=\"First\"><span class=\"Italics\">Hypersensitivity Reactions</span></p><p>Hypersensitivity reactions have been reported with MOUNJARO in the pool of placebo-controlled trials, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of MOUNJARO-treated patients compared to 1.7% of placebo-treated patients.</p><p>In the pool of seven clinical trials<span class=\"Italics\">,</span> hypersensitivity reactions occurred in 106/2,570 (4.1%) of MOUNJARO-treated patients with anti-tirzepatide antibodies and in 73/2,455 (3.0%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s70\">12.6</a>)].</span></p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s28\"></a><a name=\"section-6.1.5.4\"></a><p></p><p class=\"First\"><span class=\"Italics\">Injection Site Reactions</span></p><p>In the pool of placebo-controlled trials, injection site reactions were reported in 3.2% of MOUNJARO-treated patients compared to 0.4% of placebo-treated patients.</p><p>In the pool of seven clinical trials, injection site reactions occurred in 119/2,570 (4.6%) of MOUNJARO-treated patients with anti-tirzepatide antibodies and in 18/2,455 (0.7%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s70\">12.6</a>)].</span></p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s29\"></a><a name=\"section-6.1.5.5\"></a><p></p><p class=\"First\"><span class=\"Italics\">Acute Gallbladder Disease</span></p><p>In the pool of placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s29a\"></a><a name=\"section-6.1.5.6\"></a><p></p><p class=\"First\"><span class=\"Italics\">Dysesthesia</span></p><p>In the pool of placebo-controlled clinical trials, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo.  </p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s29b\"></a><a name=\"section-6.1.5.7\"></a><p></p><p class=\"First\"><span class=\"Italics\">Dysgeusia</span></p><p>In the pool of placebo-controlled clinical trials, dysgeusia was reported by 0.1% of MOUNJARO-treated patients and 0% of placebo-treated patients.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s30\"></a><a name=\"section-6.1.6\"></a><p></p><p class=\"First\"><span class=\"Underline\">Laboratory Abnormalities</span></p><p><span class=\"Italics\">Amylase and Lipase Increase</span></p><p>In the pool of placebo-controlled clinical trials, treatment with MOUNJARO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 33% to 38% and serum lipase concentrations of 31% to 42%. Placebo-treated patients had a mean increase from baseline in pancreatic amylase of 4% and no changes were observed in lipase. The clinical significance of elevations in lipase or amylase with MOUNJARO is unknown in the absence of other signs and symptoms of pancreatitis.</p></div></div><div class=\"Section\" data-sectioncode=\"90375-7\"><a name=\"s31\"></a><a name=\"section-6.2\"></a><p></p><h2>6.2 Postmarketing Experience</h2><p class=\"First\">The following adverse reactions have been reported during post-approval use of MOUNJARO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p><p><span class=\"Italics\">Hypersensitivity</span>: anaphylaxis, angioedema</p><p><span class=\"Italics\">Gastrointestinal</span>: ileus</p><p><span class=\"Italics\">Pulmonary</span>: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.</p></div></section>",
    "drugInteractions": "<section class=\"Section\" data-sectioncode=\"34073-7\"><a name=\"s32\"></a><a name=\"section-7\"></a><p></p><h1>7 DRUG INTERACTIONS</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s33\"></a><a name=\"section-7.1\"></a><p></p><h2>7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin</h2><p class=\"First\">When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s12\">5.3</a>)].</span></p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s34\"></a><a name=\"section-7.2\"></a><p></p><h2>7.2 Oral Medications</h2><p class=\"First\">MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO.</p><p>Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with MOUNJARO.</p><p>Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO. Hormonal contraceptives that are not administered orally should not be affected <span class=\"Italics\">[see Use in Specific Populations (<a href=\"#s44\">8.3</a>) and Clinical Pharmacology (<a href=\"#s54\">12.2</a>, <a href=\"#s59\">12.3</a>)].</span></p></div></section>",
    "clinicalPharmacology": "<section class=\"Section\" data-sectioncode=\"34090-1\"><a name=\"s52\"></a><a name=\"section-11\"></a><p></p><h1>12 CLINICAL PHARMACOLOGY</h1><div class=\"Section\" data-sectioncode=\"43679-0\"><a name=\"s53\"></a><a name=\"section-11.1\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\"First\">Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.</p><p>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.</p></div><div class=\"Section\" data-sectioncode=\"43681-6\"><a name=\"s54\"></a><a name=\"section-11.2\"></a><p></p><h2>12.2 Pharmacodynamics</h2><p class=\"First\">Tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients with type 2 diabetes mellitus.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s55\"></a><a name=\"section-11.2.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">First and Second-Phase Insulin Secretion</span></p><p>Tirzepatide enhances the first- and second-phase insulin secretion. (<a href=\"#fig1\">Figure 1</a>)<br/><br/></p><p class=\"MultiMediaCaption\"><a name=\"fig1\"></a><span class=\"Bold\">Figure 1: Mean insulin concentration at 0-120 minutes during hyperglycemic clamp at baseline and Week 28</span></p><div class=\"Figure\"><a name=\"f02\"></a><img alt=\"Figure 1\n\" src=\"moun-uspi-f1-v1.jpg\"/></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s56\"></a><a name=\"section-11.2.2\"></a><p></p><p class=\"First\"><span class=\"Italics\">Insulin Sensitivity</span></p><p>Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study after 28 weeks of treatment.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s57\"></a><a name=\"section-11.2.3\"></a><p></p><p class=\"First\"><span class=\"Italics\">Glucagon Secretion</span></p><p>Tirzepatide reduces fasting and postprandial glucagon concentrations. Tirzepatide 15 mg reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43%, compared with no change for placebo after 28 weeks of treatment.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s58\"></a><a name=\"section-11.2.4\"></a><p></p><p class=\"First\"><span class=\"Italics\">Gastric Emptying</span></p><p>Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. Tirzepatide slows post-meal glucose absorption, reducing postprandial glucose.</p></div></div><div class=\"Section\" data-sectioncode=\"43682-4\"><a name=\"s59\"></a><a name=\"section-11.3\"></a><p></p><h2>12.3 Pharmacokinetics</h2><p class=\"First\">The pharmacokinetics of tirzepatide is similar between healthy subjects and patients with type 2 diabetes mellitus. Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration. Tirzepatide exposure increases in a dose-proportional manner.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s60\"></a><a name=\"section-11.3.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Absorption</span></p><p>Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours. The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s61\"></a><a name=\"section-11.3.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Distribution</span></p><p>The mean apparent steady-state volume of distribution of tirzepatide following subcutaneous administration in patients with type 2 diabetes mellitus is approximately 10.3 L. Tirzepatide is highly bound to plasma albumin (99%).</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s62\"></a><a name=\"section-11.3.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">Elimination</span></p><p>The apparent population mean clearance of tirzepatide is 0.061 L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s63\"></a><a name=\"section-11.3.3.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Metabolism</span></p><p>Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid and amide hydrolysis.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s64\"></a><a name=\"section-11.3.3.2\"></a><p></p><p class=\"First\"><span class=\"Italics\">Excretion</span></p><p>The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s65\"></a><a name=\"section-11.3.4\"></a><p></p><p class=\"First\"><span class=\"Underline\">Specific Populations</span></p><p>The intrinsic factors of age, gender, race, ethnicity, or body weight do not have a clinically relevant effect on the PK of tirzepatide.</p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s66\"></a><a name=\"section-11.3.4.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Patients with Renal Impairment</span></p><p>Renal impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5 mg dose was evaluated in patients with different degrees of renal impairment (mild, moderate, severe, ESRD) compared with subjects with normal renal function. This was also shown for patients with both type 2 diabetes mellitus and renal impairment based on data from clinical studies <span class=\"Italics\">[see Use in Specific Populations (<a href=\"#s48\">8.6</a>)]</span>.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s67\"></a><a name=\"section-11.3.4.2\"></a><p></p><p class=\"First\"><span class=\"Italics\">Patients with Hepatic Impairment</span></p><p>Hepatic impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5 mg dose was evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) compared with subjects with normal hepatic function <span class=\"Italics\">[see Use in Specific Populations (<a href=\"#s49\">8.7</a>)]</span>.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s68\"></a><a name=\"section-11.3.5\"></a><p></p><p class=\"First\"><span class=\"Underline\">Drug Interactions Studies</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s69\"></a><a name=\"section-11.3.5.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Potential for Tirzepatide to Influence the Pharmacokinetics of Other Drugs</span></p><p>In vitro studies have shown low potential for tirzepatide to inhibit or induce CYP enzymes, and to inhibit drug transporters.</p><p>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications <span class=\"Italics\">[see Drug Interactions (<a href=\"#s34\">7.2</a>)]</span>.</p><p>The impact of tirzepatide on gastric emptying was greatest after a single dose of 5 mg and diminished after subsequent doses.</p><p>Following a first dose of tirzepatide 5 mg, acetaminophen maximum concentration (C<span class=\"Sub\">max</span>) was reduced by 50%, and the median peak plasma concentration (t<span class=\"Sub\">max</span>) occurred 1 hour later. After coadministration at week 4, there was no meaningful impact on acetaminophen C<span class=\"Sub\">max</span> and t<span class=\"Sub\">max</span>. Overall acetaminophen exposure (AUC<span class=\"Sub\">0-24hr</span>) was not influenced.</p><p>Following administration of a combined oral contraceptive (0.035 mg ethinyl estradiol and 0.25 mg norgestimate) in the presence of a single dose of tirzepatide 5 mg, mean C<span class=\"Sub\">max</span> of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%,66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively. A delay in t<span class=\"Sub\">max</span> of 2.5 to 4.5 hours was observed.</p></div></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s70\"></a><a name=\"section-11.4\"></a><p></p><h2>12.6 Immunogenicity</h2><p class=\"First\">The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the trials described below with the incidence of anti-drug antibodies in other trials.</p><p>During the 40- to 104-week treatment periods with ADA sampling conducted up to 44 to 108 weeks in seven clinical trials in adults with type 2 diabetes mellitus <span class=\"Italics\">[see Clinical Studies (<a href=\"#s73\">14</a>)],</span> 51% (2,570/5,025) of MOUNJARO-treated patients developed anti-tirzepatide antibodies. In these trials, anti-tirzepatide antibody formation in 34% and 14% of MOUNJARO-treated patients showed cross-reactivity to native GIP or native GLP-1, respectively.</p><p>Of the 2,570 MOUNJARO-treated patients who developed anti-tirzepatide antibodies during the treatment periods in these seven trials, 2% and 2% developed neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors, respectively, and 0.9% and 0.4% developed neutralizing antibodies against native GIP or GLP-1, respectively.</p><p>There was no identified clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of MOUNJARO. More MOUNJARO-treated patients who developed anti-tirzepatide antibodies experienced hypersensitivity reactions or injection site reactions than those who did not develop these antibodies <span class=\"Italics\">[see Adverse Reactions (<a href=\"#s19\">6.1</a>)].</span></p></div></section>",
    "clinicalStudies": "<section class=\"Section\" data-sectioncode=\"34092-7\"><a name=\"s73\"></a><a name=\"section-13\"></a><p></p><h1>14 CLINICAL STUDIES</h1><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s74\"></a><a name=\"section-13.1\"></a><p></p><h2>14.1 Overview of Clinical Studies</h2><p class=\"First\">The effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus was established in five trials. In these trials, MOUNJARO was studied as monotherapy (SURPASS-1); as an add-on to metformin, sulfonylureas, and/or sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) (SURPASS-2, -3, and -4); and in combination with basal insulin with or without metformin (SURPASS-5). In these trials, MOUNJARO (5 mg, 10 mg, and 15 mg given subcutaneously once weekly) was compared with placebo, semaglutide 1 mg, insulin degludec, and/or insulin glargine.</p><p>In adult patients with type 2 diabetes mellitus, treatment with MOUNJARO produced a statistically significant reduction from baseline in HbA1c compared to placebo. The effectiveness of MOUNJARO was not impacted by age, gender, race, ethnicity, region, or by baseline BMI, HbA1c, diabetes duration, or renal function.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s75\"></a><a name=\"section-13.2\"></a><p></p><h2>14.2 Monotherapy Use of MOUNJARO in Adult Patients with Type 2 Diabetes Mellitus</h2><p class=\"First\">SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type 2 diabetes mellitus with inadequate glycemic control with diet and exercise to MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg, or placebo once weekly.</p><p>Patients had a mean age of 54 years, and 52% were men. The mean duration of type 2 diabetes mellitus was 4.7 years, and the mean BMI was 32 kg/m<span class=\"Sup\">2</span>. Overall, 36% were White, 35% were Asian, 25% were American Indians/Alaska Natives, and 5% were Black or African American; 43% identified as Hispanic or Latino ethnicity.</p><p>Monotherapy with MOUNJARO 5 mg, 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see <a href=\"#t3\">Table 3</a>).</p><a name=\"t3\"></a><table width=\"100%\"><caption><span>Table 3: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise</span></caption><col align=\"left\" width=\"28.374%\"/><col align=\"left\" width=\"18.836%\"/><col align=\"left\" width=\"17.596%\"/><col align=\"left\" width=\"17.596%\"/><col align=\"left\" width=\"17.596%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 25%, 2%, 3%, and 2% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c data were missing for 12%, 6%, 7%, and 14% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">c</span> p&lt;0.001 (two-sided) for superiority vs. placebo, adjusted for multiplicity.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">d</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Placebo</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>5 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>10 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Modified Intent-to-Treat (mITT) Population (N)<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">113</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">121</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">121</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">120</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">HbA1c (%)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">7.9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">7.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.7</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from placebo<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.7<span class=\"Sup\">c</span><br/>(-2.0, -1.4)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.6<span class=\"Sup\">c</span><br/>(-1.9, -1.3)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.6<span class=\"Sup\">c</span><br/>(-1.9, -1.3)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Patients (%) achieving HbA1c &lt;7%<span class=\"Sup\">d</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">23</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">82<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">85<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">78<span class=\"Sup\">c</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fasting Serum Glucose (mg/dL)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">155</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">154</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">153</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">154</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-40</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-40</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-39</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from <br/>     placebo<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-43<span class=\"Sup\">c</span><br/>(-55, -32)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-43<span class=\"Sup\">c</span><br/>(-55, -32)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-42<span class=\"Sup\">c</span><br/>(-54, -30)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Body Weight (kg)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">84.5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">87.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">86.2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">85.5</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-6.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-7.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-7.8</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from <br/>     placebo<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-5.3<span class=\"Sup\">c</span><br/>(-6.8, -3.9)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-6.0<span class=\"Sup\">c</span><br/>(-7.4, -4.6)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-6.8<span class=\"Sup\">c</span><br/>(-8.3, -5.4)</td></tr></tbody></table></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s76\"></a><a name=\"section-13.3\"></a><p></p><h2>14.3 MOUNJARO Use in Combination with Metformin, Sulfonylureas, and/or SGLT2 Inhibitors in Adult Patients with Type 2 Diabetes Mellitus</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s77\"></a><a name=\"section-13.3.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Add-on to metformin</span></p><p>SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1879 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of MOUNJARO 5 mg, MOUNJARO 10 mg, or MOUNJARO 15 mg once weekly or subcutaneous semaglutide 1 mg once weekly.</p><p>Patients had a mean age of 57 years and 47% were men. The mean duration of type 2 diabetes mellitus was 8.6 years, and the mean BMI was 34 kg/m<span class=\"Sup\">2</span>. Overall, 83% were White, 4% were Black or African American, and 1% were Asian; 70% identified as Hispanic or Latino ethnicity.</p><p>Treatment with MOUNJARO 10 mg and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with semaglutide 1 mg once weekly (see <a href=\"#t4\">Table 4</a> and <a href=\"#fig2\">Figure 2</a>).</p><a name=\"t4\"></a><table width=\"100%\"><caption><span>Table 4: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1 mg in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin</span></caption><col align=\"left\" width=\"43.160%\"/><col align=\"left\" width=\"13.700%\"/><col align=\"left\" width=\"13.500%\"/><col align=\"left\" width=\"14.820%\"/><col align=\"left\" width=\"14.820%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 3%, 2%, 1%, and 1% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 5%, 4%, 5%, and 5% of patients randomized to semaglutide 1 mg, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">c</span> p&lt;0.05 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">d</span> p&lt;0.001 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">e</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">f</span> p&lt;0.01 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Semaglutide <br/>1 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>5 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>10 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Modified Intent-to-Treat (mITT) Population (N)<span class=\"Bold\"><span class=\"Sup\">a</span></span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">468</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">470</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">469</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">469</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">HbA1c (%)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.3</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.3</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from semaglutide<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.2<span class=\"Sup\">c</span><br/>(-0.3, -0.0)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.4<span class=\"Sup\">d</span><br/>(-0.5, -0.3)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.5<span class=\"Sup\">d</span><br/>(-0.6, -0.3)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Patients (%) achieving HbA1c &lt;7%<span class=\"Sup\">e</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">79</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">82</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">86<span class=\"Sup\">f</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">86<span class=\"Sup\">f</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fasting Serum Glucose (mg/dL)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">171</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">174</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">174</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">172</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-49</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-55</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-59</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-60</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Body Weight (kg)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">93.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">92.5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">94.8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">93.8</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-5.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-7.6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-9.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-11.2</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from semaglutide<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.9<span class=\"Sup\">c</span><br/>(-2.8, -1.0)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-3.6<span class=\"Sup\">d</span><br/>(-4.5, -2.7)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-5.5<span class=\"Sup\">d</span><br/>(-6.4, -4.6)</td></tr></tbody></table><p class=\"MultiMediaCaption\"><a name=\"fig2\"></a><span class=\"Bold\">Figure 2. Mean HbA1c (%) Over Time - Baseline to Week 40</span></p><div class=\"Figure\"><a name=\"f03\"></a><img alt=\"Figure 2\n\" src=\"moun-uspi-f2-v1.jpg\"/></div><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"15.599%\"/><col align=\"left\" width=\"5.053%\"/><col align=\"left\" width=\"6.538%\"/><col align=\"left\" width=\"6.538%\"/><col align=\"left\" width=\"6.538%\"/><col align=\"left\" width=\"6.538%\"/><col align=\"left\" width=\"6.538%\"/><col align=\"left\" width=\"6.538%\"/><col align=\"left\" width=\"6.538%\"/><col align=\"left\" width=\"11.276%\"/><col align=\"left\" width=\"6.615%\"/><col align=\"left\" width=\"5.784%\"/><col align=\"left\" width=\"9.907%\"/><tbody class=\"Headless\"><tr><td align=\"right\" valign=\"top\"><span class=\"Bold\">Number of patients</span></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td></tr><tr><td align=\"right\" valign=\"top\"><span class=\"Bold\">MOUNJARO 5mg</span></td><td align=\"right\" valign=\"top\">470</td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\">451</td><td align=\"right\" valign=\"top\">470</td><td align=\"right\" valign=\"top\"></td></tr><tr><td align=\"right\" valign=\"top\"><span class=\"Bold\">MOUNJARO 10mg</span></td><td align=\"right\" valign=\"top\">469</td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\">445</td><td align=\"right\" valign=\"top\">469</td><td align=\"right\" valign=\"top\"></td></tr><tr><td align=\"right\" valign=\"top\"><span class=\"Bold\">MOUNJARO 15mg</span></td><td align=\"right\" valign=\"top\">469</td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\">447</td><td align=\"right\" valign=\"top\">469</td><td align=\"right\" valign=\"top\"></td></tr><tr><td align=\"right\" valign=\"top\"><span class=\"Bold\">Semaglutide 1mg</span></td><td align=\"right\" valign=\"top\">468</td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\"></td><td align=\"right\" valign=\"top\">443</td><td align=\"right\" valign=\"top\">468</td><td align=\"right\" valign=\"top\"></td></tr></tbody></table><p>Note: Displayed results are from modified Intent-to-Treat Full Analysis Set. (1) Observed mean value from Week 0 to Week 40, and (2) least-squares mean ± standard error at Week 40 multiple imputation (MI).</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s78\"></a><a name=\"section-13.3.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Add-on to metformin with or without SGLT2 inhibitor</span></p><p>SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1444 adult patients with type 2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin degludec 100 units/mL once daily. In this trial, 32% of patients were on SGLT2 inhibitor. Insulin degludec was initiated at 10 units once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 26% of patients randomized to insulin degludec achieved the fasting serum glucose target of &lt;90 mg/dL, and the mean daily insulin degludec dose was 49 U (0.5 U per kilogram).</p><p>Patients had a mean age of 57 years, and 56% were men. The mean duration of type 2 diabetes mellitus was 8.4 years, and the mean baseline BMI was 34 kg/m<span class=\"Sup\">2</span>. Overall, 91% were White, 3% were Black or African American, and 5% were Asian; 29% identified as Hispanic or Latino ethnicity.</p><p>Treatment with MOUNJARO 10 mg and 15 mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with daily insulin degludec (see <a href=\"#t5\">Table 5</a>).</p><a name=\"t5\"></a><table width=\"100%\"><caption><span>Table 5: Results at Week 52 in a Trial of MOUNJARO versus Insulin Degludec in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin with or without SGLT2 Inhibitor</span></caption><col align=\"left\" width=\"40.528%\"/><col align=\"left\" width=\"14.883%\"/><col align=\"left\" width=\"14.863%\"/><col align=\"left\" width=\"14.863%\"/><col align=\"left\" width=\"14.863%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%,1%, 1%, and 2% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 6%, 10%, and 5% of patients randomized to insulin degludec, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">c</span> p&lt;0.001 (two-sided) for superiority vs. insulin degludec, adjusted for multiplicity.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">d</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Insulin Degludec</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>5 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>10 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Modified Intent-to-Treat (mITT)<span class=\"Sup\">a</span> Population (N)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">359</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">358</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">360</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">358</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">HbA1c (%)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.2</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 52<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.1</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from insulin degludec<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.6<span class=\"Sup\">c</span><br/>(-0.7, -0.5)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.8<span class=\"Sup\">c</span><br/>(-0.9, -0.6)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.9<span class=\"Sup\">c</span><br/>(-1.0, -0.7)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Patients (%) achieving HbA1c &lt;7%<span class=\"Sup\">d</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">58</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">79<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">82<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">83<span class=\"Sup\">c</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fasting Serum Glucose (mg/dL)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">167</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">172</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">170</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">168</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 52<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-51</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-47</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-50</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-54</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Body Weight (kg)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">94.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">94.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">93.8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">94.9</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 52<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-7.0</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-9.6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-11.3</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from insulin degludec<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-8.9<span class=\"Sup\">c</span><br/>(-10.0, -7.8)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-11.5<span class=\"Sup\">c</span><br/>(-12.6, -10.4)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-13.2<span class=\"Sup\">c</span><br/>(-14.3, -12.1)</td></tr></tbody></table></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s79\"></a><a name=\"section-13.3.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea or SGLT-2 inhibitor)</span></p><p>SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%).</p><p>Patients had a mean age of 64 years, and 63% were men. The mean duration of type 2 diabetes mellitus was 11.8 years, and the mean baseline BMI was 33 kg/m<span class=\"Sup\">2</span>. Overall, 82% were White, 4% were Black or African American, and 4% were Asian; 48% identified as Hispanic or Latino ethnicity. Across all treatment groups, 87% had a history of cardiovascular disease. At baseline, eGFR was ≥90 mL/min/1.73 m<span class=\"Sup\">2</span> in 43%, 60 to 90 mL/min/1.73 m<span class=\"Sup\">2</span> in 40%, 45 to 60 mL/min/1.73 m<span class=\"Sup\">2</span> in 10%, and 30 to 45 mL/min/1.73 m<span class=\"Sup\">2</span> in 6% of patients.</p><p>Insulin glargine was initiated at 10 U once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 30% of patients randomized to insulin glargine achieved the fasting serum glucose target of &lt;100 mg/dL, and the mean daily insulin glargine dose was 44 U (0.5 U per kilogram).</p><p>Treatment with MOUNJARO 10 mg and 15 mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with insulin glargine once daily (see <a href=\"#t6\">Table 6</a>).</p><a name=\"t6\"></a><table width=\"100%\"><caption><span>Table 6: Results at Week 52 in a Trial of MOUNJARO versus Insulin Glargine in Adult Patients with Type 2 Diabetes Mellitus Added to Metformin and/or Sulfonylurea and/or SGLT2 Inhibitor</span></caption><col align=\"left\" width=\"43.691%\"/><col align=\"left\" width=\"13.777%\"/><col align=\"left\" width=\"14.177%\"/><col align=\"left\" width=\"14.177%\"/><col align=\"left\" width=\"14.177%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%, 0%, 0%, and 1% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 9%, 6%, and 4% of patients randomized to insulin glargine, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">c</span> p&lt;0.001 (two-sided) for superiority vs. insulin glargine, adjusted for multiplicity.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">d</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Insulin Glargine</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>5 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>10 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Modified Intent-to-Treat (mITT) Population (N)<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">998</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">328</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">326</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">337</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">HbA1c (%)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.5</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 52<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.4</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from insulin glargine<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.7<span class=\"Sup\">c</span><br/>(-0.9, -0.6)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.9<span class=\"Sup\">c</span><br/>(-1.1, -0.8)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.0<span class=\"Sup\">c</span><br/>(-1.2, -0.9)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Patients (%) achieving HbA1c &lt;7%<span class=\"Sup\">d</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">49</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">75<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">83<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">85<span class=\"Sup\">c</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fasting Serum Glucose (mg/dL)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">168</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">172</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">176</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">174</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 52<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-49</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-44</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-50</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-55</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Body Weight (kg)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">90.2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">90.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">90.6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">90.0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 52<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.7</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-6.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-8.9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-10.6</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from insulin glargine<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-8.1<span class=\"Sup\">c</span><br/>(-8.9, -7.3)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-10.6<span class=\"Sup\">c</span><br/>(-11.4, -9.8)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-12.2<span class=\"Sup\">c</span><br/>(-13.0, -11.5)</td></tr></tbody></table></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s80\"></a><a name=\"section-13.4\"></a><p></p><h2>14.4 MOUNJARO Use in Combination with Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus</h2><p class=\"First\">SURPASS-5 (NCT04039503) was a 40-week double-blind trial that randomized 475 patients with type 2 diabetes mellitus with inadequate glycemic control on insulin glargine 100 units/mL, with or without metformin, to MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or placebo. The dose of background insulin glargine was adjusted using a treat-to-target algorithm based on self-measured fasting blood glucose values, targeting &lt;100 mg/dL.</p><p>Patients had a mean age of 61 years, and 56% were men. The mean duration of type 2 diabetes mellitus was 13.3 years, and the mean baseline BMI was 33 kg/m<span class=\"Sup\">2</span>. Overall, 80% were White, 1% were Black or African American, and 18% were Asian; 5% identified as Hispanic or Latino ethnicity.</p><p>The mean dose of insulin glargine at baseline was 34, 32, 35, and 33 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively. At randomization, the initial insulin glargine dose in patients with HbA1c ≤8.0% was reduced by 20%. At week 40, mean dose of insulin glargine was 38, 36, 29, and 59 units/day for patients receiving MOUNJARO 5 mg, 10 mg, 15 mg, and placebo, respectively.</p><p>Treatment with MOUNJARO 5 mg once weekly, 10 mg once weekly and 15 mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see <a href=\"#t7\">Table 7</a>).</p><a name=\"t7\"></a><table width=\"100%\"><caption><span>Table 7: Results at Week 40 in a Trial of MOUNJARO Added to Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus</span></caption><col align=\"left\" width=\"44.449%\"/><col align=\"left\" width=\"13.183%\"/><col align=\"left\" width=\"14.123%\"/><col align=\"left\" width=\"14.123%\"/><col align=\"left\" width=\"14.123%\"/><tfoot><tr class=\"First\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">a</span> The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 4%, 1%, 0%, and 1% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. At Week 40 the HbA1c endpoint was missing for 2%, 6%, 3%, and 7% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">b</span> Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">c</span> p&lt;0.001 (two-sided) for superiority vs. placebo, adjusted for multiplicity.</p></td></tr><tr class=\"Last\"><td align=\"left\" colspan=\"5\" valign=\"top\"><p class=\"First Footnote\"><span class=\"Sup\">d</span> Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Placebo</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>5 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>10 mg</span></td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">MOUNJARO<br/>15 mg</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Modified Intent-to-Treat (mITT) Population (N)<span class=\"Sup\">a</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">119</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">116</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">118</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">118</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">HbA1c (%)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.3</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">8.2</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-0.9</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.1</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-2.3</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from placebo<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.2<span class=\"Sup\">c</span><br/>(-1.5, -1.0)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.5<span class=\"Sup\">c</span><br/>(-1.8, -1.3)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-1.5<span class=\"Sup\">c</span><br/>(-1.7, -1.2)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Patients (%) achieving HbA1c &lt;7%<span class=\"Sup\">d</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">35</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">87<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">90<span class=\"Sup\">c</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">85<span class=\"Sup\">c</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Fasting Serum Glucose (mg/dL)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">164</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">163</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">163</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">160</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-39</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-58</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-64</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-63</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from placebo<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-19<span class=\"Sup\">c</span><br/>(-27, -11)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-25<span class=\"Sup\">c</span><br/>(-32, -17)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-23<span class=\"Sup\">c</span><br/>(-31, -16)</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">Body Weight (kg)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Baseline (mean)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">94.2</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">95.8</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">94.6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">96.0</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Change at Week 40<span class=\"Sup\">b</span></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">1.6</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-5.4</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-7.5</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-8.8</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">     Difference from placebo<span class=\"Sup\">b</span> (95% CI)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">--</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-7.1<span class=\"Sup\">c</span><br/>(-8.7, -5.4)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-9.1<span class=\"Sup\">c</span><br/>(-10.7, -7.5)</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\">-10.5<span class=\"Sup\">c</span><br/>(-12.1, -8.8)</td></tr></tbody></table></div></section>",
    "howSupplied": "<section class=\"Section\" data-sectioncode=\"34069-5\"><a name=\"s82\"></a><a name=\"section-14.1\"></a><p></p><h2>16.1 How Supplied</h2><p class=\"First\">MOUNJARO is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens or 1 single-dose vial as follows:</p><table width=\"100%\"><col align=\"left\" width=\"30.823%\"/><col align=\"left\" width=\"37.054%\"/><col align=\"left\" width=\"32.123%\"/><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Total Strength per Total Volume</span></td><td align=\"left\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold Underline\">Pen </span><span class=\"Bold\">NDC</span></td><td align=\"left\" class=\"Botrule Rrule Toprule\" valign=\"top\"><span class=\"Bold Underline\">Vial </span><span class=\"Bold\">NDC</span></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">2.5 mg/0.5 mL</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-1506-80</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-1152-01</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">5 mg/0.5 mL</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-1495-80</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-1243-01</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">7.5 mg/0.5 mL</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-1484-80</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-2214-01</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">10 mg/0.5 mL</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-1471-80</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-2340-01</td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">12.5 mg/0.5 mL</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-1460-80</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-2423-01</td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\">15 mg/0.5 mL</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-1457-80</td><td align=\"left\" class=\"Botrule Rrule\" valign=\"top\">0002-3002-01</td></tr></tbody></table></section>",
    "useInSpecificPopulations": "<section class=\"Section\" data-sectioncode=\"43684-0\"><a name=\"s35\"></a><a name=\"section-8\"></a><p></p><h1>8 USE IN SPECIFIC POPULATIONS</h1><div class=\"Section\" data-sectioncode=\"42228-7\"><a name=\"s36\"></a><a name=\"section-8.1\"></a><p></p><h2>8.1 Pregnancy</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s37\"></a><a name=\"section-8.1.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Risk Summary</span></p><p>Available data with MOUNJARO use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy <span class=\"Italics\">(see Clinical Considerations)</span>. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>In pregnant rats administered tirzepatide during organogenesis, fetal growth reductions and fetal abnormalities occurred at clinical exposure in maternal rats based on AUC. In rabbits administered tirzepatide during organogenesis, fetal growth reductions were observed at clinically relevant exposures based on AUC. These adverse embryo/fetal effects in animals coincided with pharmacological effects on maternal weight and food consumption <span class=\"Italics\">(see Data)</span>.</p><p>The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an HbA1c &gt;7% and has been reported to be as high as 20–25% in women with an HbA1c &gt;10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.</p></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s38\"></a><a name=\"section-8.1.2\"></a><p></p><p class=\"First\"><span class=\"Underline\">Clinical Considerations</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s39\"></a><a name=\"section-8.1.2.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Disease-Associated Maternal and/or Embryo/Fetal Risk</span></p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</p></div></div><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s40\"></a><a name=\"section-8.1.3\"></a><p></p><p class=\"First\"><span class=\"Underline\">Data</span></p><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s41\"></a><a name=\"section-8.1.3.1\"></a><p></p><p class=\"First\"><span class=\"Italics\">Animal Data</span></p><p>In pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5 mg/kg tirzepatide (0.03-, 0.07-, and 0.5-fold the MRHD of 15 mg once weekly based on AUC) during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5 mg/kg. In pregnant rabbits given once weekly subcutaneous doses of 0.01, 0.03, or 0.1 mg/kg tirzepatide (0.01-, 0.06-, and 0.2-fold the MRHD) during organogenesis, pharmacologically-mediated effects on the gastrointestinal system resulting in maternal mortality or abortion in a few rabbits occurred at all dose levels. Reduced fetal weights associated with decreased maternal food consumption and body weights were observed at 0.1 mg/kg. In a pre- and post-natal study in rats administered subcutaneous doses of 0.02, 0.10, or 0.25 mg/kg tirzepatide twice weekly from implantation through lactation, F<span class=\"Sub\">1</span> pups from F<span class=\"Sub\">0</span> maternal rats given 0.25 mg/kg tirzepatide had statistically significant lower mean body weight when compared to controls from post-natal day 7 through post-natal day 126 for males and post-natal day 56 for females.</p></div></div></div><div class=\"Section\" data-sectioncode=\"77290-5\"><a name=\"s42\"></a><a name=\"section-8.2\"></a><p></p><h2>8.2 Lactation</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s43\"></a><a name=\"section-8.2.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Risk Summary</span></p><p>There are no data on the presence of tirzepatide in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for MOUNJARO and any potential adverse effects on the breastfed infant from MOUNJARO or from the underlying maternal condition.</p></div></div><div class=\"Section\" data-sectioncode=\"77291-3\"><a name=\"s44\"></a><a name=\"section-8.3\"></a><p></p><h2>8.3 Females and Males of Reproductive Potential</h2><div class=\"Section\" data-sectioncode=\"42229-5\"><a name=\"s45\"></a><a name=\"section-8.3.1\"></a><p></p><p class=\"First\"><span class=\"Underline\">Contraception</span></p><p>Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO <span class=\"Italics\">[see Drug Interactions (<a href=\"#s34\">7.2</a>) and Clinical Pharmacology (<a href=\"#s54\">12.2</a>, <a href=\"#s59\">12.3</a>)].</span></p></div></div><div class=\"Section\" data-sectioncode=\"34081-0\"><a name=\"s46\"></a><a name=\"section-8.4\"></a><p></p><h2>8.4 Pediatric Use</h2><p class=\"First\">Safety and effectiveness of MOUNJARO have not been established in pediatric patients.</p></div><div class=\"Section\" data-sectioncode=\"34082-8\"><a name=\"s47\"></a><a name=\"section-8.5\"></a><p></p><h2>8.5 Geriatric Use</h2><p class=\"First\">In the pool of seven clinical trials, 1539 (30.1%) MOUNJARO-treated patients were 65 years of age or older, and 212 (4.1%) MOUNJARO-treated patients were 75 years of age or older at baseline.</p><p>No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p></div><div class=\"Section\" data-sectioncode=\"88828-9\"><a name=\"s48\"></a><a name=\"section-8.6\"></a><p></p><h2>8.6 Renal Impairment</h2><p class=\"First\">No dosage adjustment of MOUNJARO is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no change in tirzepatide pharmacokinetics (PK) was observed <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s59\">12.3</a>)]</span>. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe adverse gastrointestinal reactions <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s14\">5.5</a>)].</span></p></div><div class=\"Section\" data-sectioncode=\"88829-7\"><a name=\"s49\"></a><a name=\"section-8.7\"></a><p></p><h2>8.7 Hepatic Impairment</h2><p class=\"First\">No dosage adjustment of MOUNJARO is recommended for patients with hepatic impairment. In a clinical pharmacology study in subjects with varying degrees of hepatic impairment, no change in tirzepatide PK was observed <span class=\"Italics\">[see Clinical Pharmacology (<a href=\"#s59\">12.3</a>)]</span>.</p></div></section>",
    "description": "<section class=\"Section\" data-sectioncode=\"34089-3\"><a name=\"s51\"></a><a name=\"section-10\"></a><p></p><h1>11 DESCRIPTION</h1><p class=\"First\">MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. Tirzepatide is based on the GIP sequence and contains aminoisobutyric acid (Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C<span class=\"Sub\">225</span>H<span class=\"Sub\">348</span>N<span class=\"Sub\">48</span>O<span class=\"Sub\">68</span>.</p><p>Structural formula:</p><div class=\"Figure\"><a name=\"f01\"></a><img alt=\"Structural Formula\n\" src=\"moun-uspi-chem-struc.jpg\"/></div><p>MOUNJARO is a clear, colorless to slightly yellow, sterile, preservative-free solution for subcutaneous use. Each single-dose pen or single-dose vial contains a 0.5 mL solution of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg of tirzepatide and the following excipients: sodium chloride (4.1 mg), sodium phosphate dibasic heptahydrate (0.7 mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may have been added to adjust the pH. MOUNJARO has a pH of 6.5 – 7.5.</p></section>",
    "nonclinicalToxicology": "<section class=\"Section\" data-sectioncode=\"43680-8\"><a name=\"s71\"></a><a name=\"section-12\"></a><p></p><h1>13 NONCLINICAL TOXICOLOGY</h1><div class=\"Section\" data-sectioncode=\"34083-6\"><a name=\"s72\"></a><a name=\"section-12.1\"></a><p></p><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p class=\"First\">A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5 mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15 mg once weekly based on AUC) administered by subcutaneous injection twice weekly. A statistically significant increase in thyroid C-cell adenomas was observed in males (≥0.5 mg/kg) and females (≥0.15 mg/kg), and a statistically significant increase in thyroid C-cell adenomas and carcinomas combined was observed in males and females at all doses examined. In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10 mg/kg administered by subcutaneous injection twice weekly was not tumorigenic.</p><p>Tirzepatide was not genotoxic in a rat bone marrow micronucleus assay.</p><p>In fertility and early embryonic development studies, male and female rats were administered twice weekly subcutaneous doses of 0.5, 1.5, or 3 mg/kg (0.3-, 1-, and 2-fold and 0.3-, 0.9-, and 2-fold, respectively, the MRHD of 15 mg once weekly based on AUC). No effects of tirzepatide were observed on sperm morphology, mating, fertility, and conception. In female rats, an increase in the number of females with prolonged diestrus and a decrease in the mean number of corpora lutea resulting in a decrease in the mean number of implantation sites and viable embryos was observed at all dose levels. These effects were considered secondary to the pharmacological effects of tirzepatide on food consumption and body weight.</p></div></section>",
    "instructionsForUse": "<section class=\"Section\" data-sectioncode=\"59845-8\"><a name=\"s98\"></a><a name=\"section-18\"></a><p></p><h1>Mounjaro Single-Dose Vial Instructions for Use</h1><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"100%\"/><tbody class=\"Headless\"><tr><td align=\"justify\" valign=\"bottom\"><span class=\"Bold\">INSTRUCTIONS FOR USE</span><br/><span class=\"Bold\">MOUNJARO<span class=\"Sup\">®</span> [mown-JAHR-OH]</span><br/><span class=\"Bold\">(tirzepatide)</span><br/><span class=\"Bold\">injection, for subcutaneous use</span><br/><br/><span class=\"Bold\">2.5 mg/0.5 mL single-dose vial</span><br/><span class=\"Bold\">5 mg/0.5 mL single-dose vial</span><br/><span class=\"Bold\">7.5 mg/0.5 mL single-dose vial</span><br/><span class=\"Bold\">10 mg/0.5 mL single-dose vial</span><br/><span class=\"Bold\">12.5 mg/0.5 mL single-dose vial</span><br/><span class=\"Bold\">15 mg/0.5 mL single-dose vial</span></td></tr></tbody></table><p class=\"First\"><span class=\"Bold\">Important information you need to know before injecting MOUNJARO</span></p><p><span class=\"Bold\">Read this Instructions for Use before you start taking MOUNJARO and each time you get a new vial.</span> There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.      </p><p><span class=\"Bold\">Do not share your needles or syringes with other people. You may give other people a serious infection or get a serious infection from them.</span></p><p>Talk to your healthcare provider about how to inject MOUNJARO the right way.</p><ul class=\"Disc\"><li>MOUNJARO is a single-dose vial.</li><li>MOUNJARO is used 1 time each week.</li><li>Inject under the skin (subcutaneously) only.</li><li>You or another person may inject into your stomach (abdomen) or thigh.</li><li>Another person can inject into the back of your upper arm.</li></ul><p><span class=\"Bold\">Gather supplies needed to give your injection</span></p><ul class=\"Disc\"><li>1 single-dose MOUNJARO vial</li><li>1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)</li><li>1 alcohol swab</li><li>gauze</li><li>1 sharps container for throwing away used needles and syringes. <span class=\"Bold\">See</span> “Disposing of used needles and syringes” at the end of these instructions.</li></ul><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"20.000%\"/><col align=\"left\" width=\"80.000%\"/><tbody class=\"Headless\"><tr><td align=\"center\" valign=\"middle\"><span class=\"Bold\">Guide to parts<br/><br/>Vial</span></td><td align=\"center\" valign=\"middle\"><span class=\"Bold\">Needle and Syringe (not included)</span></td></tr><tr><td align=\"center\" valign=\"middle\"><a name=\"f34a\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-1-v1.jpg\"/></td><td align=\"center\" valign=\"middle\"><a name=\"f34b\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-2-v1.jpg\"/></td></tr></tbody></table><p><span class=\"Bold\">Note:</span> The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.</p><p><span class=\"Bold\">Preparing to inject MOUNJARO</span></p><p><span class=\"Bold\">Remove the vial</span>  from the refrigerator.      </p><p><span class=\"Bold\">Check the vial</span> label to make sure you have the right medicine and dose, and that it has not expired.      </p><p>Make sure the medicine:</p><table class=\"Noautorules\" width=\"100%\"><col align=\"left\" width=\"50%\"/><col align=\"left\" width=\"50%\"/><tbody class=\"Headless\"><tr><td align=\"left\"><ul class=\"Disc\"><li>is not frozen</li><li>is not cloudy</li></ul></td><td align=\"left\"><ul class=\"Disc\"><li>is colorless to slightly yellow</li><li>does not have particles</li></ul></td></tr></tbody></table><p><span class=\"Bold\">Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.</span></p><p><span class=\"Bold\">Wash your hands with soap and water.</span></p><table width=\"100%\"><col align=\"left\" width=\"53.250%\"/><col align=\"left\" width=\"46.750%\"/><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Step 1:</span><br/>Pull off the plastic protective cap. <span class=\"Bold\">Do not</span> remove the rubber stopper.</td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><a name=\"f35\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-3-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 2:</span><br/>Wipe the rubber stopper with an alcohol swab.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f36\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-4-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 3:</span><br/>Remove the outer wrapping from the syringe.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f37\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-5-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 4:</span><br/>Remove the outer wrapping from the needle.<br/>The syringe that your healthcare provider recommended may have a pre-attached needle. If the needle is attached, skip to step 6.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f38\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-6-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 5:</span><br/>Place the needle on top of the syringe and turn until it is tight and firmly attached.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f39\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-7-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 6:</span><br/>Remove the needle shield by pulling straight off.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f40\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-8-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 7:</span><br/>Hold the syringe in one hand with the needle pointing up. With the other hand pull down on the plunger until the plunger tip reaches the line on the syringe indicating that 0.5 mL of air has been drawn into the syringe.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f41\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-9-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 8:</span><br/>Push the needle through the rubber stopper of the vial.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><br/><a name=\"f42\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-10-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 9:</span><br/>Push the plunger all the way in. This puts air into the vial and makes it easier to pull the solution from the vial.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><br/><a name=\"f43\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-11-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Step 10: </span><br/>Turn the vial and syringe upside down. Make sure that the tip of the needle is in the liquid and slowly pull the plunger down until the plunger tip is past the 0.5 mL line.<br/> If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top.</td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><a name=\"f44\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-12-v1.jpg\"/><a name=\"f45\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-13-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 11:</span><br/>Slowly push the plunger up until the plunger tip reaches the 0.5 mL line.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f46\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-14-v1.jpg\"/></td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 12:</span><br/>Pull the syringe out of the rubber stopper of the vial.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f47\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-15-v1.jpg\"/></td></tr></tbody></table><p><span class=\"Bold\">Injecting MOUNJARO </span></p><ul class=\"Disc\"><li>Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.</li><li><span class=\"Bold\">Change (rotate) your injection site within the area you choose for each dose</span> to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.</li><li><span class=\"Bold\">Do not</span> inject where the skin has pits, is thickened, or has lumps.</li><li><span class=\"Bold\">Do not</span> inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.</li><li><span class=\"Bold\">Do not</span> mix MOUNJARO with any other medicine.</li><li><span class=\"Bold\">Do not</span> inject MOUNJARO in the same injection site used for other medicines.</li></ul><table width=\"100%\"><col align=\"left\" width=\"53.250%\"/><col align=\"left\" width=\"46.750%\"/><tbody class=\"Headless\"><tr class=\"First\"><td align=\"left\" class=\"Botrule Lrule Rrule Toprule\" valign=\"top\"><span class=\"Bold\">Step 13: </span><br/>Choose your injection site. <br/> You can inject MOUNJARO under the skin (subcutaneously) of your stomach area (abdomen) or thighs. <br/> Someone else can inject in your stomach area, thighs, or the back of the upper arms.</td><td align=\"center\" class=\"Botrule Rrule Toprule\" valign=\"top\"><a name=\"f48\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-16-v1.jpg\"/><a name=\"f49\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-17-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 14:</span><br/>Insert the needle into your skin.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f50\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-18-v1.jpg\"/></td></tr><tr><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 15:</span><br/>Push down on the plunger to inject your dose.          <br/>The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your dose.</td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f51\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-19-v1.jpg\"/></td></tr><tr class=\"Last\"><td align=\"left\" class=\"Botrule Lrule Rrule\" valign=\"top\"><span class=\"Bold\">Step 16:</span><br/>Pull the needle out of your skin.<br/><ul class=\"Disc\"><li>If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. <span class=\"Bold\">Do not</span> rub the area.</li><li><span class=\"Bold\">Do not</span> recap the needle. Recapping the needle can lead to a needle stick injury.</li></ul></td><td align=\"center\" class=\"Botrule Rrule\" valign=\"top\"><a name=\"f52\"></a><img alt=\"Figure\n\" src=\"moun-vial-ifu-20-v1.jpg\"/></td></tr></tbody></table><p><span class=\"Bold\">Disposing of used needles and syringes</span></p><ul class=\"Disc\"><li>Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use. <span class=\"Bold\">Do not</span> throw away (dispose of) loose needles and syringes in your household trash.</li><li>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:       <dl><dt>-</dt><dd> made of a heavy-duty plastic,</dd><dt>-</dt><dd> can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</dd><dt>-</dt><dd> upright and stable during use,</dd><dt>-</dt><dd> leak-resistant, and</dd><dt>-</dt><dd> properly labeled to warn of hazardous waste inside the container.</dd></dl></li><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: <br/> http://www.fda.gov/safesharpsdisposal.</li><li><span class=\"Bold\">Do not</span> dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. <span class=\"Bold\">Do not</span> recycle your used sharps disposal container.</li></ul><p><span class=\"Bold\">Storing MOUNJARO</span></p><ul class=\"Disc\"><li>Store all unopened vials in the refrigerator at 36°F to 46°F (2°C to 8°C).</li><li>You may store the unopened vial at room temperature up to 86°F (30°C) for up to 21 days.</li><li><span class=\"Bold\">Do not</span> freeze. <span class=\"Bold\">Do not</span> use if MOUNJARO has been frozen.</li><li>Store the vial in the original carton to protect from light.</li><li>Throw away all opened vials after use, even if there is medicine left in the vial.</li></ul><p><span class=\"Bold\">Keep MOUNJARO vials, syringes, needles, and all medicines out of the reach of children.</span></p><p>If you have any questions or problems with your MOUNJARO, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.</p><p><span class=\"Bold\">Marketed by:<br/> Lilly USA, LLC  <br/> Indianapolis, IN 46285, USA</span></p><p>MOUNJARO is a registered trademark of Eli Lilly and Company.</p><p>Copyright © 2023, 2024, Eli Lilly and Company. All rights reserved.</p><p>MON-VL-0002-IFU-20240229</p><p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p><p>Revised: February 2024</p></section>",
    "mechanismOfAction": "<section class=\"Section\" data-sectioncode=\"43679-0\"><a name=\"s53\"></a><a name=\"section-11.1\"></a><p></p><h2>12.1 Mechanism of Action</h2><p class=\"First\">Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.</p><p>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.</p></section>",
    "contraindications": "<section class=\"Section\" data-sectioncode=\"34070-3\"><a name=\"s8\"></a><a name=\"section-4\"></a><p></p><h1>4 CONTRAINDICATIONS</h1><p class=\"First\">MOUNJARO is contraindicated in patients with:</p><ul class=\"Disc\"><li>A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s10\">5.1</a>)]</span>.</li><li>Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO <span class=\"Italics\">[see Warnings and Precautions (<a href=\"#s13\">5.4</a>)]</span>.</li></ul></section>",
    "highlights": {
      "dosageAndAdministration": "<div><ul class=\"Disc\"><li>The recommended starting dosage is 2.5 mg injected subcutaneously once weekly (<a href=\"#s5\">2.1</a>)</li><li>After 4 weeks, increase to 5 mg injected subcutaneously once weekly (<a href=\"#s5\">2.1</a>)</li><li>If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.</li><li>The maximum dosage is 15 mg subcutaneously once weekly (<a href=\"#s5\">2.1</a>).</li><li>Administer once weekly at any time of day, with or without meals. (<a href=\"#s6\">2.2</a>)</li><li>Inject subcutaneously in the abdomen, thigh, or upper arm. (<a href=\"#s6\">2.2</a>)</li><li>Rotate injection sites with each dose.</li></ul></div>"
    }
  }
}